

September 17, 2018

**Anticipated backorder of Sandoz Haloperidol LA (decanoate) 100 mg/mL 5 mL vials**

Dear customer,

On July 30, 2018, we announced that we would be temporarily instituting a stock protection and allocation system for Haloperidol LA (decanoate) 100 mg/mL 5 mL vials. The release of new lots that meet our rigorous quality requirements is expected on December 17, 2018. Until then, we anticipate that the following product will be on backorder as of September 25, 2018:

Sandoz Material/Article	Description	DIN	UPC
44005220	Haloperidol LA (decanoate) 100 mg/mL 5 mL vials	02130300	57513029400

While Sandoz Canada is the only supplier of the injectable long acting (LA) form in Canada, other forms of haloperidol as well as alternative therapies are available for patients. They should contact their physician if necessary.

We are doing our best to minimize the impact on our customers and patients. Please do not hesitate to submit an emergency allocation order (EAO) request if this product is needed. We will analyze and answer EAO requests in a timely matter.

We are fully aware of our medication's importance to patients. This is why we adhere to rigorous international quality and ethical standards, which ensure that we deliver safe and effective products. We have informed Health Canada about this issue and will continue to provide timely and accurate information to healthcare professionals and our customers about any developments.

Should you have any questions, please contact your local Sandoz representative, our Customer Service department at 1-800-361-3062 or our Drug Information and Pharmacovigilance team at 1-800-343-8839, extension 4636.

Thank you for your understanding,

**Martin Arès**

Vice President, Generics & Specialty Products